Online inquiry

IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2722MR)

This product GTTS-WQ2722MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19&CD3E gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001178098.2; NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930; 916
UniProt ID P15391; P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2722MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12797MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ12361MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ4971MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ191MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ7827MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ12044MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ5672MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ10784MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW